💰The Funding Letter #1352: February 14

BioAge Labs, Antithesis, Bob W, and more...

February 14, 2024


Good Morning! This exclusive edition of The Funding Letter comes to you from our headquarters in New York City. 🔥New Sales Gigs from Unlearn below!

Hit the Gong 🎉

Source: @overheard_sales

Looking for visuals and charts, rather than words, to understand the daily news?

Bay Area Times is a visual-based newsletter on business and tech, with 250,000+ subscribers.

Daily Deals 💸

🌎 Americas

BioAge Labs provides drug therapy to treat specific age-related diseases and to extend human health span and lifespan, enabling people to combat the suffering and disability caused by all aging-related diseases and restore both the quality and quantity of life in old age. View on: LinkedIn.com | Sales Navigator.

New Funding Raised: $170M, Series D

Round Investors: Sofinnova Investments (lead), OrbiMed, Lilly Ventures, Andreessen Horowitz

🚀Growth Focus: Advance Phase 2 clinical trials of azelaprag, an apelin receptor agonist, in combination with Lilly’s Zepboundand therapeutic pipeline.

HQ: Richmond, CA

Industry: Biotechnology Research

Employee Count: 80

Subscribe to TFL All-Access Tier to read the rest.

Become a paying subscriber of TFL All-Access Tier to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In.

A subscription gets you:

  • • Exclusive Access to The Funding Letter, delivering hundreds of leads to your inbox each month
  • • Searchable weekly, monthly, and annual datasets of funding announcement leads, so you can quickly find the most relevant data
  • • The hottest Sales Gigs in the industry, sourced from the fastest growing startups
  • • ..and much more to come!